GALLANT-1: Galectin-3 (Gal-3) inhibitor, GB1211, plus atezolizumab (atz) in patients (pts) with non-small cell lung cancer (NSCLC) - a dose finding study followed by a randomised, double-blind, placebo-controlled trial

被引：1
|
作者：
Ghiringhelli, F. [1 ]
Barre, P. [2 ]
Pichon, E. [3 ]
Aix, S. Ponce [4 ]
Vidal, O. J. Juan [5 ]
Costa, E. Carcereny [6 ]
Sethi, T. [7 ]
Lindmark, B. [8 ]
MacKinnon, A. [7 ]
Aslanis, V. [9 ]
Phung, D. H. [10 ]
Jensen, P. [11 ]
Rajiwate, Z. [12 ]
Ross, G. [8 ]
Basse, L. [8 ]
机构：
[1] Univ Burgundy, Genet & Immuno therapy Med Inst, Ctr Georges Francois Leclerc, Dijon, France
[2] Montpellier Reg Univ Hosp, Dept Thorac Oncol, Montpellier, France
[3] CHRU Bretonneau, Serv Pneumol, Tours, France
[4] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
[5] La Fe Univ Hosp, Dept Med Oncol, Valencia, Spain
[6] Germans Trias & Pujol Hosp, Catalan Inst Oncol Badalona, Dept Med Oncol, Barcelona, Spain
[7] Galecto Biotech AB, Pre Clin Res & Dev, Copenhagen, Denmark
[8] Galecto Biotech AB, Clin Res & Dev, Copenhagen, Denmark
[9] Galecto Biotech AB, Pharmacokinet, Copenhagen, Denmark
[10] Galecto Biotech AB, Biostat, Copenhagen, Denmark
[11] Galecto Biotech AB, Project Management, Copenhagen, Denmark
[12] Galecto Biotech AB, Clin Operat, Copenhagen, Denmark
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1315
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1192TiP
引用
收藏
页码：S1093 / S1094
页数：2
相关论文
共 50 条
  • [21] MONET 1-AN INTERNATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF MOTESANIB IN COMBINATION WITH CARBOPLATIN/PACLITAXEL IN PATIENTS WITH ADVANCED NONSQUAMOUS NON-SMALL-CELL LUNG CANCER (NSCLC)
    Scagliotti, Giorgio
    Vynnychenko, Ihor
    Ichinose, Yukito
    Park, Keunchil
    Kubota, Kaoru
    Blackhall, Fiona
    Pirker, Robert
    Popovych, Oleksandr
    Galiulin, Rinat
    Ciuleanu, Tudor-Eliade
    Sydorenko, Oleksandr
    Dediu, Mircea
    Papai-Szekely, Zsolt
    Martinez Banaclocha, Natividad
    Mccoy, Sheryl
    Yao, Bin
    Hei, Yong-Jiang
    Spigel, David R.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S276 - S277
  • [22] Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
    Spicer, Jonathan D.
    Garassino, Marina C.
    Wakelee, Heather
    Liberman, Moishe
    Kato, Terufumi
    Tsuboi, Masahiro
    Lee, Se-Hoon
    Chen, Ke-Neng
    Dooms, Christophe
    Majem, Margarita
    Eigendorff, Ekkehard
    Martinengo, Gaston L.
    Bylicki, Olivier
    Rodriguez-Abreu, Delvys
    Chaft, Jamie E.
    Novello, Silvia
    Yang, Jing
    Arunachalam, Ashwini
    Keller, Steven M.
    Samkari, Ayman
    Gao, Shugeng
    LANCET, 2024, 404 (10459): : 1240 - 1252
  • [23] EFFICACY ANALYSIS FOR MOLECULAR SUBGROUPS IN MARQUEE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF TIVANTINIB (ARQ 197) PLUS ERLOTINIB VERSUS PLACEBO PLUS ERLOTINIB IN PREVIOUSLY TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC, NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (NSCLC)
    Novello, Silvia
    Scagliotti, Giorgio
    Ramlau, Rodryg
    Favaretto, Adolfo
    Barlesi, Fabrice
    Akerley, Wallace
    Von Pawel, Joachim
    Orlov, Sergey
    Spigel, David R.
    Santoro, Armando
    Shepherd, Frances
    Hirsh, Vera
    Sequist, Lecia V.
    Shuster, Dale
    Zahir, Hamim
    Wang, Qiang
    Schwartz, Brian
    Von Roemeling, Reinhard
    Sandler, Allan B.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S901 - S902
  • [24] A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC)
    Sandler, A.
    Schiller, J. H.
    Hirsh, V.
    Sequist, L. V.
    Soria, J.
    Von Pawel, J.
    Wang, Q.
    Pande, A. U.
    Schwartz, B. E.
    Garmey, E. G.
    Gorbatchevsky, I.
    Scagliotti, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] S1206: A dose-finding study followed by a phase II randomized placebo-controlled trial of chemoradiotherapy (CRT) with or without veliparib in stage Ill non-small cell lung cancer (NSCLC).
    Argiris, Athanassios
    Miao, Jieling
    Cristea, Mihaela C.
    Chen, Allen M.
    Sands, Jacob
    Decker, Roy H.
    Gettinger, Scott N.
    Daly, Megan Eileen
    Faller, Bryan A.
    Albain, Kathy S.
    Yanagihara, Ronald H.
    Garland, Linda L.
    Byers, Lauren Averett
    Wang, Ding
    Koczywas, Marianna
    Redman, Mary Weber
    Kelly, Karen
    Gandara, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
    Lee, Siow Ming
    Khan, Iftekhar
    Upadhyay, Sunil
    Lewanski, Conrad
    Falk, Stephen
    Skailes, Geraldine
    Marshall, Ernie
    Woll, Penella J.
    Hatton, Matthew
    Lal, Rohit
    Jones, Richard
    Toy, Elizabeth
    Chao, David
    Middleton, Gary
    Bulley, Sue
    Ngai, Yenting
    Rudd, Robin
    Hackshaw, Allan
    Boshoff, Chris
    LANCET ONCOLOGY, 2012, 13 (11): : 1161 - 1170
  • [27] A phase II multicenter, randomized, placebo controlled, double-blind study of CC-486 plus pembrolizumab (pembro) vs pembro plus placebo (PBO) in previously treated patients (pts) with locally advanced/metastatic non-small cell lung cancer (NSCLC).
    Levy, Benjamin Philip
    Giaccone, Giuseppe
    Besse, Benjamin
    Begic, Damir
    Wu, Xiaoling
    Fandi, Abderrahim
    Paz-Ares, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer
    Novello, Silvia
    Kaiser, Rolf
    Mellemgaard, Anders
    Douillard, Jean-Yves
    Orlov, Sergey
    Krzakowski, Maciej
    von Pawel, Joachim
    Gottfried, Maya
    Bondarenko, Igor
    Liao, Meilin
    Barrueco, Jose
    Gaschler-Markefski, Birgit
    Griebsch, Ingolf
    Palmer, Michael
    Reck, Martin
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (03) : 317 - 326
  • [29] A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ONARTUZUMAB (METMAB) WITH EITHER BEVACIZUMAB plus PLATINUM plus PACLITAXEL OR PEMETREXED plus PLATINUM AS FIRST-LINE TREATMENT FOR PATIENTS (PTS) WITH STAGE IIIB OR IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Wakelee, H.
    Yu, W.
    Rittweger, K.
    Paton, V. E.
    ANNALS OF ONCOLOGY, 2012, 23 : 445 - 445
  • [30] A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ONARTUZUMAB (METMAB) IN COMBINATION WITH PACLITAXEL plus CISPLATIN (OR CARBOPLATIN) AS FIRST-LINE TREATMENT FOR PATIENTS (PTS) WITH STAGE IIIB OR IV SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Hirsch, F. R.
    Gandara, D.
    Govindan, R.
    Paton, V. E.
    Yu, W.
    ANNALS OF ONCOLOGY, 2012, 23 : 445 - 445
12345